Management of nosocomial pneumonia - State of the art;Die nosokomiale pneumonie - State-of-the-art

Intensivmedizin und Notfallmedizin

Volumn 43, Issue 4, 2006, Pages 301-309

  Welte, T ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Antibiotics; Diagnosis; Nosocomial pneumonia; Therapy

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN;

ANTIBIOTIC THERAPY; CLINICAL TRIAL; DECISION MAKING; EVALUATION; HOSPITAL CARE; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; MORBIDITY; MORTALITY; NURSING; PATHOPHYSIOLOGY; REVIEW; RISK ASSESSMENT; TREATMENT FAILURE;

EID: 33745144266     PISSN: 01753851     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00390-006-0721-2     Document Type: Review

References (49)

1. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, Wolff M, Spencer RC, Hemmer M (1995) The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 274(8):639-644
2. Alberti C, Brun-Buisson C, Chevret S, Antonelli M, Goodman SV, Martin C, Moreno R, Ochagavia AR, Palazzo M, Werdan K, Le Gall JR (2005) European Sepsis Study Group.Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. Am J Respir Crit Care Med 171(5):461-468
3. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C (2003) Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med (12):2742-2751
4. Dietrich ES, Demmler M, Schulgen G, Fekec K, Mast O, Pelz K, Daschner FD (2002) Nosocomial pneumonia: a cost-of-illness analysis. Infection 30 (2):61-67
5. Cosgrove SE (2006) The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 42(Suppl 2:S82-89
6. Pletz MW, Welte T (2005) Pneumonie. In: Dietel M, Suttorp N, Zeitz M (Hrsg) Harrison's Innere Medizin (dt. Ausgabe), ABW Wissenschaftsverlag GmbH, Berlin, S 1638-1650
7. Gastmeier P, Sohr D, Geffers C, Behnke M, Daschner F, Ruden H (2005) Mortality risk factors with nosocomial Staphylococcus aureus infections in intensive care units: results from the German Nosocomial Infection Surveillance System (KISS). Infection 33(2):50-55
8. Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348(16): 1546-1554
9. el-Ebiary M, Torres A, Fabregas N, de la Bellacasa JP, Gonzalez J, Ramirez J, del Bano D, Hernandez C, Jimenez de Anta MT (1997) Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study. Am J Respir Crit Care Med 156(2 Pt 1):583-590
10. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E (2004) Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 170(6):621-625
11. National Nosocomial Infections Surveillance System (2004) National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32(8):470-485
12. Huotari K, Tarkka E, Valtonen V, Kolho E (2003) Incidence and risk factors for nosocomial infections caused by fluoroquinolone-resistant Escherichia coli. Eur J Clin Microbiol Infect Dis 22(8):492-495
13. Hong T, Moland ES, Abdalhamid B, Hanson ND, Wang J, Sloan C, Fabian D, Farajallah A, Levine J, Thomson KS (2005) Escherichia coli: development of carbapenem resistance during therapy. Clin Infect Dis 40(10):e84-86
14. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP (2003) Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289(7):885-888
15. Grundmann H, Barwolff S, Tami A, Behnke M, Schwab F, Geffers C, Halle E, Gobel UB, Schiller R, Jonas D, Klare I, Weist K, Witte W, Beck-Beilecke K, Schumacher M, Ruden H, Gastmeier P (2005) How many infections are caused by patient-to-patient transmission in intensive care units? Crit Care Med 33(5):946-951
16. Goossens H, Ferech M, Vander Stichele R, Elseviers M (2005) Outpatient antibiotic use in Europe and association with resistance: a cross national database study. Lancet 365:579-587
17. Welte T (2004) Epidemiological impact of antibiotic use/misuse in the community. Eur Respir Mon 28:165-174
18. Pletz MW, McGee L, Van Beneden CA, Petit S, Bardsley M, Barlow M, Klugman KP (2006) Fluoroquinolone resistance in invasive Streptococcus pyogenes isolates due to spontaneous mutation and horizontal gene transfer. Antimicrob Agents Chemother 50(3):943-948
19. Namias N, Samiian L, Nino D, Shirazi E, O'Neill K, Kett DH, Ginzburg E, McKenney MG, Sleeman D, Cohn SM (2000) Incidence and susceptibility of pathogenic bacteria vary between intensive care units within a single hospital: implications for empiric antibiotic strategies. J Trauma 49(4):638-645
20. Metlay JP, Schulz R, Li YH, Singer DE, Marrie TJ, Coley CM, Hough LJ, Obrosky DS, Kapoor WN, Fine MJ (1997) Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 157(13):1453-1459
21. Hopstaken RM, Butler CC, Muris JW, Knottnerus JA, Kester AD, Rinkens PE, Dinant GJ (2006) Do clinical findings in lower respiratory tract infection help general practitioners prescribe antibiotics appropriately? An observational cohort study in general practice. Fam Pract 23(2):180-187
22. Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM (1991) Diagnosis of ventilator-associated pneumonia by bacterologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar fluid. Am Rev Respir Dis 143:1121-1129
23. Kollef MH, Von Harz B, Prentice D, Shapiro SD, Silver P, St John R, Trovillion E (1997) Patient transport from intensive care increases the risk of developing ventilator-associated pneumonia. Chest 112(3):765-773
24. Christ-Grain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Müller B (2004) Effect of procalcitonin guided treatment on antibiotic use and outcome in lower respiratory tract infections. Lancet 363:600-607
25. Ewig S, de Roux A, Bauer T, Garcia E, Mensa J, Niederman M, Torres A (2004) Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax 59(5):421-427
26. Fagon JY, Chastre J, Wolff M, Gervais C, Parer-Aubas S, Stephan F, Similowski T, Mercat A, Diehl JL, Sollet JP, Tenaillon A (2000) Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 132(8):621-630
27. Ruiz M, Torres A, Ewig S, Marcos MA, Alcon A, Lledo R, Asenjo MA, Maldonaldo A (2000) Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: evaluation of outcome. Am J Respir Crit Care Med 162(1):119-125
28. Maskell NA, Gleeson FV, Darby M et al (2004) Diagnostically significant variations in pleural fluid pH in loculated parapneumonic effusions Chest 126:2022-2024
29. Hoffken G, Lorenz J, Kern W, Welte T, Bauer T, Dalhoff K, Dietrich E, Ewig S, Gastmeier P, Grabein B, Halle E, Kolditz M, Marre R, Sitter H (2005) S3-Leitlinie zu ambulant erworbener Pneumonie und tiefen Atemwegsinfektionen. Pneumologie 59(9):612-664
30. Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R (2004) CDC; Healthcare Infection Control Practices Advisory Committee. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 53(RR-3): 1-36
31. Valles J, Rello J, Ochagavia A, Garnacho J, Alcala MA (2003) Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest 123(5):1615-1624
32. Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, Jolly EC (1997) Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 111(3):676-685
33. Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, Gibert C (1998) Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Grit Care Med 157(2):531-539
34. American Thoracic Society; Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171(4):388-416
35. Sandiumenge A, Diaz E, Bodi M, Rello J (2003) Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of "The Tarragona Strategy". Intensive Care Med 29(6):876-883
36. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL (2000) Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 162(2 Pt 1):505-511
37. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S (2003) PneumA Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290(19):2588-2598
38. Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX, Tannenberg AM (2004) Efficacy of 750-mg, 5-day levofloxacin in the treatment of community acquired pneumonia caused by atypical pathogens. Curr Med Res Opin 20(4):555-563
39. Halm EA, Teirstein AS (2002) Clinical practice. Managment of community-acquired pneumonia. N Engl J Med 347(25):2039-2045
40. Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, Torres A (2002) Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 162:1849-1858
41. Giantsou E, Liratzopoulos N, Efraimidou E, Panopoulou M, Alepopoulou E, Kartali-Ktenidou S, Minopoulos GI, Zakynthinos S, Manolas KI (2005) Both early-onset and late-onset ventilator associated-pneumonia are caused mainly by potentially multiresistant bacteria. Intensive Care Med 31(11):1488-1494
42. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L (2004) Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 328(7441):668
43. Safdar N, Handelsman J, Maki DG (2004) Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A metaanalysis. Lancet Infect Dis 4(8):519-527
44. Hoffman LR, D'Argenio DA, MacCoss MJ, Zhang Z, Jones RA, Miller SI (2005) Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 436(7054):1171-1175
45. Chamot E, Boffi El Amari E, Rohner P, Van Delden C (2003) Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 47(9):2756-2764
46. Mayer I, Nagy E (1999) Investigation of the synergic effects of aminoglycoside-fluoroquinolone and third-generation cephalosporin combinations against clinical isolates of Pseudomonas spp. J Antimicrob Chemother 43(5):651-657
47. Burkhardt O, Derendorf H, Welte T (2006) Neue Antibiotika für die Behandlung von MRSA-Infektionen. Med Monatsschr Pharm 29(2):56-62
48. Rello J, Sole-Violan J, Sa-Borges M, Garnacho-Montero J, Munoz E, Sirgo G, Olona M, Diaz E (2005) Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 33(9):1983-1987
49. Welte T (2006) Arzneimittelkommission der deutschen Ärzteschaft (Hrsg) Arzneiverordnungen. Deutscher Ärzte-Verlag, Köln, S 879-891